On 29 January 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, opened the 2025 Initial Public Offering (IPO) season and announced the launch of its IPO on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The company’s most advanced R&D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in Lille, France, Delaware, United States and Guangzhou, China.
The IPO, which successfully occurred on 7 February 2025, comprised a primary offering targeting gross proceeds of CHF 80 million (including an over-allotment option targeting gross proceeds of CHF 5 million). At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys AG was around CHF 216 million.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud & Cie SA and Octavian AG as Selling Agents.